Vaccine developed by AstraZeneca most likely to protect for a year: CEO
Follow UsStory highlights
The British drugmaker has signed contracts with France, Germany, Italy and the Netherlands to supply the EU with up to 400 million doses of the vaccine.
AstraZeneca is one of the front runners in the race to protect against coronavirus for about a year, the company's chief executive told a Belgian radio station on Tuesday.
The vaccines developed by the University of Oxford have begun with human trials with a phase I trial in Britain due to end soon and a phase III trial already begun, Pascal Soriot told broadcaster Bel RTL.
"We think that it will protect for about a year," Soriot said.
The British drugmaker has signed contracts with France, Germany, Italy and the Netherlands to supply the EU with up to 400 million doses of the vaccine.
Britain and the United States are also a part of the deal.
"If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well," Soriot said.
(Inputs from Reuters)